» Articles » PMID: 34888350

Experimental and Meta-Analytic Validation of RNA Sequencing Signatures for Predicting Status of Microsatellite Instability

Overview
Specialty Biology
Date 2021 Dec 10
PMID 34888350
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Microsatellite instability (MSI) is an important diagnostic and prognostic cancer biomarker. In colorectal, cervical, ovarian, and gastric cancers, it can guide the prescription of chemotherapy and immunotherapy. In laboratory diagnostics of susceptible tumors, MSI is routinely detected by the size of marker polymerase chain reaction products encompassing frequent microsatellite expansion regions. Alternatively, MSI status is screened indirectly by immunohistochemical interrogation of microsatellite binding proteins. RNA sequencing (RNAseq) profiling is an emerging source of data for a wide spectrum of cancer biomarkers. Recently, three RNAseq-based gene signatures were deduced for establishing MSI status in tumor samples. They had 25, 15, and 14 gene products with only one common gene. However, they were developed and tested on the incomplete literature of The Cancer Genome Atlas (TCGA) sampling and never validated experimentally on independent RNAseq samples. In this study, we, for the first time, systematically validated these three RNAseq MSI signatures on the literature colorectal cancer (CRC) ( = 619), endometrial carcinoma ( = 533), gastric cancer ( = 380), uterine carcinosarcoma ( = 55), and esophageal cancer ( = 83) samples and on the set of experimental CRC RNAseq samples ( = 23) for tumors with known MSI status. We found that all three signatures performed well with area under the curve (AUC) ranges of 0.94-1 for the experimental CRCs and 0.94-1 for the TCGA CRC, esophageal cancer, and uterine carcinosarcoma samples. However, for the TCGA endometrial carcinoma and gastric cancer samples, only two signatures were effective with AUC 0.91-0.97, whereas the third signature showed a significantly lower AUC of 0.69-0.88. Software for calculating these MSI signatures using RNAseq data is included.

Citing Articles

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.

Poddubskaya E, Suntsova M, Lyadova M, Luppov D, Guryanova A, Lyadov V Front Immunol. 2024; 15:1493877.

PMID: 39723204 PMC: 11669362. DOI: 10.3389/fimmu.2024.1493877.


Detecting microsatellite instability by length comparison of microsatellites in the 3' untranslated region with RNA-seq.

Choi J, Lee J, Lee S Brief Bioinform. 2024; 25(5).

PMID: 39210504 PMC: 11361843. DOI: 10.1093/bib/bbae423.


Frequency of HER2 Expression, MMR Deficiency, and PI3KCA Mutation in Pretreated Surgical Specimens of Patients with Esophageal Squamous Cell Carcinoma in Iran Cancer Institute.

Salarvand Farzaneh Bagheri S, Gholizadeh M, Sharifi S, Panahi P, Esmati E, Lashkari M Iran J Pathol. 2023; 18(1):96-103.

PMID: 37383157 PMC: 10293601. DOI: 10.30699/IJP.2023.563358.2989.


Cancer-specific functional profiling in microsatellite-unstable (MSI) colon and endometrial cancers using combined differentially expressed genes and biclustering analysis.

Na W, Lee I, Koh I, Kwon M, Song Y, Lee S Medicine (Baltimore). 2023; 102(19):e33647.

PMID: 37171359 PMC: 10174364. DOI: 10.1097/MD.0000000000033647.


Clinically relevant fusion oncogenes: detection and practical implications.

Sorokin M, Rabushko E, Rozenberg J, Mohammad T, Seryakov A, Sekacheva M Ther Adv Med Oncol. 2023; 14:17588359221144108.

PMID: 36601633 PMC: 9806411. DOI: 10.1177/17588359221144108.


References
1.
Hartmann A, Zanardo L, Bocker-Edmonston T, Blaszyk H, Dietmaier W, Stoehr R . Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res. 2002; 62(23):6796-802. View

2.
Pannafino G, Alani E . Coordinated and Independent Roles for MLH Subunits in DNA Repair. Cells. 2021; 10(4). PMC: 8074049. DOI: 10.3390/cells10040948. View

3.
Johansen A, Kassentoft C, Knudsen M, Laursen M, Madsen A, Iversen L . Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients. BMC Cancer. 2019; 19(1):971. PMC: 6802299. DOI: 10.1186/s12885-019-6227-7. View

4.
Buhard O, Cattaneo F, Wong Y, Yim S, Friedman E, Flejou J . Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol. 2005; 24(2):241-51. DOI: 10.1200/JCO.2005.02.7227. View

5.
Ryan E, Sheahan K, Creavin B, Mohan H, Winter D . The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. Crit Rev Oncol Hematol. 2017; 116:38-57. DOI: 10.1016/j.critrevonc.2017.05.006. View